PMID- 21073994
OWN - NLM
STAT- MEDLINE
DCOM- 20110303
LR  - 20151119
IS  - 0003-4509 (Print)
IS  - 0003-4509 (Linking)
VI  - 68
IP  - 6
DP  - 2010 Nov
TI  - [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: 
      expected progresses--raised problems].
PG  - 359-69
LID - 10.1016/j.pharma.2010.08.001 [doi]
AB  - After having been used for decades, heparins (unfractionated heparin [UFH] or low 
      molecular weight heparins [LMWH]) and vitamin K antagonists (VKA), which are only 
      parenterally active or which are responsible for frequent iatrogenicity 
      respectively, have to face the competition of new anticoagulant drugs targeting 
      either factor Xa or factor IIa (thrombin). Rivaroxaban (Xarelto((R))) and 
      Dabigatran Etexilate (Pradaxa((R))) are the two leading components. They are more 
      convenient to use and do not require routine coagulation monitoring. They are 
      already marketed for venous thromboembolism prevention in major orthopaedic 
      surgery. Although manufacturers claim that no biological monitoring is required, 
      these two compounds may interfere in routine coagulation tests such as PT or 
      aPTT, and in esoteric assays such as anti-Xa activity (the results of which are 
      usually expressed in international anti-Xa units either UFH or LMWH unit) for 
      Rivaroxaban or anti-IIa activity for Dabigatran Etexilate. Noteworthy is the fact 
      that, in the case of these new anticoagulant drugs, results should be expressed 
      in active product units (nanogram per millilitre of Rivaroxaban or Dabigatran). 
      The new anticoagulants are associated with a bleeding risk comparable to that of 
      VKA and heparins.
CI  - Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
FAU - Samama, M
AU  - Samama M
AD  - Service d'hematologie, hotel-Dieu, AP-HP, 1 place du parvis-Notre-Dame, Paris, 
      France. mmsamama@aol.com
FAU - Conard, J
AU  - Conard J
FAU - Horellou, M-H
AU  - Horellou MH
FAU - Le Flem, L
AU  - Le Flem L
FAU - Guinet, C
AU  - Guinet C
FAU - Depasse, F
AU  - Depasse F
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Deux nouveaux anticoagulants disponibles en 2010--Dabigatran Etexilate et 
      Rivaroxaban: progres attendus--problemes poses.
DEP - 20101029
PL  - France
TA  - Ann Pharm Fr
JT  - Annales pharmaceutiques francaises
JID - 2985176R
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Morpholines)
RN  - 0 (Pyridines)
RN  - 0 (Thiophenes)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - EC 3.4.21.5 (Thrombin)
RN  - I0VM4M70GC (Dabigatran)
SB  - IM
MH  - Anticoagulants/classification/pharmacology/*therapeutic use
MH  - Benzimidazoles/pharmacology/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Dabigatran
MH  - Factor Xa Inhibitors
MH  - Humans
MH  - Morpholines/pharmacology/*therapeutic use
MH  - Pyridines/pharmacology/*therapeutic use
MH  - Rivaroxaban
MH  - Thiophenes/pharmacology/*therapeutic use
MH  - Thrombin/antagonists & inhibitors
EDAT- 2010/11/16 06:00
MHDA- 2011/03/04 06:00
CRDT- 2010/11/16 06:00
PHST- 2010/05/21 00:00 [received]
PHST- 2010/07/22 00:00 [revised]
PHST- 2010/08/03 00:00 [accepted]
PHST- 2010/11/16 06:00 [entrez]
PHST- 2010/11/16 06:00 [pubmed]
PHST- 2011/03/04 06:00 [medline]
AID - S0003-4509(10)00131-8 [pii]
AID - 10.1016/j.pharma.2010.08.001 [doi]
PST - ppublish
SO  - Ann Pharm Fr. 2010 Nov;68(6):359-69. doi: 10.1016/j.pharma.2010.08.001. Epub 2010 
      Oct 29.